• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • AstraZeneca divests Atacand’s European rights for $210m pharmaceutical-technology
    July 30, 2018
    AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to German pharmaceutical company Cheplapharm Arzneimittel for $200m.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service